Axsome Therapeutics (FRA:19X) Current Accrued Expense : €60.2 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Axsome Therapeutics Current Accrued Expense?

Axsome Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was €60.2 Mil.

Axsome Therapeutics's quarterly Current Accrued Expense increased from Sep. 2023 (€59.9 Mil) to Dec. 2023 (€64.2 Mil) but then declined from Dec. 2023 (€64.2 Mil) to Mar. 2024 (€60.2 Mil).

Axsome Therapeutics's annual Current Accrued Expense increased from Dec. 2021 (€4.6 Mil) to Dec. 2022 (€38.1 Mil) and increased from Dec. 2022 (€38.1 Mil) to Dec. 2023 (€64.2 Mil).

Axsome Therapeutics Current Accrued Expense Historical Data

The historical data trend for Axsome Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Current Accrued Expense Chart

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

8.00

4.80

4.64

38.09

64.23

Axsome Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															48.10	51.12	59.94	64.23	60.23

Axsome Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Axsome Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (FRA:19X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (FRA:19X) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

AXSM:USA 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Axsome Therapeutics (FRA:19X) Headlines

No Headlines